Janux Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−1.55%
vs ±10.7% implied · ×0.14
shaded = implied · ▲▼ = realized
Linked news
NewsNo other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Janux Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Janux Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Janux Therapeutics, Inc.
17.85
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $171.9M | 18.27% | 0.00% |
| BlackRockindex-like | $94.2M | 10.02% | +12.91% |
| Prosight | $58.4M | 6.21% | +7.17% |
| State Streetindex-like | $46.2M | 4.91% | +21.95% |
| FMR | $37.1M | 3.94% | −4.85% |
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $171.9M | 18.27% | 0.00% |
| BlackRockindex-like | $94.2M | 10.02% | +12.91% |
| Prosight | $58.4M | 6.21% | +7.17% |
| State Streetindex-like | $46.2M | 4.91% | +21.95% |
| FMR | $37.1M | 3.94% | −4.85% |
Bull1
Bear2
Expected move
Inputsspot 17.82exp Nov 20ATM strike 17.5ATM straddle 4.65IV 154%